While MCP-4 and TIM-3 were significantly elevated only in patients with COVID-19 who developed long-term neurological symptoms (MCP-4 p = 0.017, TIM-3 p = 0.0001; Figure 1D), these latter differences were not statistically significant when adjusted for disease severity. This evidence concerns the gene CCL13 and COVID-19.